Abstract
Vasoactive intestinal peptide (VIP) is a neuropeptide with a broad distribution in the body that exerts very important pleiotropic functions in several systems. The present work reviews the immunology of VIP. Being daring, this neuropeptide could be included in the group of cytokines since it is produced and secreted by different immunocompetent cells in response to various immune signals, plays a broad spectrum of immunological functions, and exerts them, in a paracrine and/orautocrine way, through three different specific receptors. Although VIP has been classically considered as an immunodepressant agent, and its main described role has been as an anti-inflammatory factor, several evidences suggest that a better way to see this peptide is as a modulator of the homeostasis of the immune system. In the last decade, the pharmacology of VIP has spectacularly grown, and VIP itself, as well as more stable VIP-derived agents, have been used or proposed as efficient therapeutical treatments of several disorders, specially inflammatory and autoimmune diseases, such as septic shock, rheumatoid arthritis, multiple sclerosis, Crohns disease and autoimmune diabetes. A broad field of perspectives is actually open, and further investigations will help us to definitively understand the immunology of this “very important peptide”
Current Pharmaceutical Design
Title: Immunology of VIP: A Review and Therapeutical Perspectives
Volume: 7 Issue: 2
Author(s): R.P. Gomariz, C. Martinez, C. Abad, J. Leceta and M. Delgado
Affiliation:
Abstract: Vasoactive intestinal peptide (VIP) is a neuropeptide with a broad distribution in the body that exerts very important pleiotropic functions in several systems. The present work reviews the immunology of VIP. Being daring, this neuropeptide could be included in the group of cytokines since it is produced and secreted by different immunocompetent cells in response to various immune signals, plays a broad spectrum of immunological functions, and exerts them, in a paracrine and/orautocrine way, through three different specific receptors. Although VIP has been classically considered as an immunodepressant agent, and its main described role has been as an anti-inflammatory factor, several evidences suggest that a better way to see this peptide is as a modulator of the homeostasis of the immune system. In the last decade, the pharmacology of VIP has spectacularly grown, and VIP itself, as well as more stable VIP-derived agents, have been used or proposed as efficient therapeutical treatments of several disorders, specially inflammatory and autoimmune diseases, such as septic shock, rheumatoid arthritis, multiple sclerosis, Crohns disease and autoimmune diabetes. A broad field of perspectives is actually open, and further investigations will help us to definitively understand the immunology of this “very important peptide”
Export Options
About this article
Cite this article as:
R.P. Gomariz , C. Martinez , C. Abad , J. Leceta and M. Delgado , Immunology of VIP: A Review and Therapeutical Perspectives, Current Pharmaceutical Design 2001; 7 (2) . https://dx.doi.org/10.2174/1381612013398374
DOI https://dx.doi.org/10.2174/1381612013398374 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences Oral Tolerance in the Treatment of Rheumatoid Arthritis
Current Drug Targets - Inflammation & Allergy Adenosine A<sub>3</sub> Receptor: A promising therapeutic target in cardiovascular disease
Current Cardiology Reviews TMJ Arthritis Imaging: Conventional Radiograph vs. CT Scan - Is CT Actually Needed?
Current Rheumatology Reviews The Influences of Aconitine, an Active/Toxic Alkaloid from Aconitum, on the Oral Pharmacokinetics of CYP3A Probe Drug Buspirone in Rats
Drug Metabolism Letters Integrin αvβ3 as a Therapeutic Target for Blocking Tumor-Induced Angiogenesis
Current Drug Targets Polyunsaturated Fatty Acids in Pregnancy and Metabolic Syndrome: A Review
Current Pharmaceutical Biotechnology Safety and Efficacy of Mavrilimumab For Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Current Rheumatology Reviews Editorial [Hot Topic: New Approaches to the Treatment of Inflammatory Disorders (Guest Editor: Mark L. Richards)]
Current Topics in Medicinal Chemistry Editorial [Hot topic: Polyunsaturated Fatty Acids and Human Health: A Critical Appraisal of the Evidence (Executive Editor: Antonio Cherubini)]
Current Pharmaceutical Design Searching for Novel Janus Kinase-2 Inhibitors Using a Combination of Pharmacophore Modeling, 3D-QSAR Studies and Virtual Screening
Mini-Reviews in Medicinal Chemistry Platelets in Angiogenesis
Current Vascular Pharmacology The Role of Macrophage Migration Inhibitory Factor in Critical Illness
Mini-Reviews in Medicinal Chemistry Synthesis and Biological Activity of a New Class of Azetidinones Compounds as Potential HLE Inhibitors
Letters in Drug Design & Discovery Antibody-Drug Conjugate Targets
Current Cancer Drug Targets Targeting Chemokine Receptor CXCR4 for Treatment of HIV-1 Infection, Tumor Progression, and Metastasis
Current Topics in Medicinal Chemistry Pathway to the Clinic: Inhibition of P38 MAP Kinase. A Review of Ten Chemotypes Selected for Development
Current Topics in Medicinal Chemistry Hsp90 Inhibition with Resorcylic Acid Lactones (RALs)
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Targeting Cell Migration - The Next Generation Blockbusters (Guest Editors: Amanda E.I. Proudfoot, Marie Kosco-Vilbois and Zoe Johnson)]
Current Immunology Reviews (Discontinued) Pharmacophore and QSAR Modeling of Neuronal Nitric Oxide Synthase Ligands and Subsequent Validation and In Silico Search for New Scaffolds
Medicinal Chemistry